RxDoctor Payments Data

Jeffrey Ferber, MD

Family Medicine · Vista, CANPI 1609890813

Payments from drug & device makers

$9,153in general payments, 2019–2025

Across 402 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$686
  • Novo Nordisk$630
  • Amgen$619
  • Pfizer$456
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$9,153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,153 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$56,406
Medicare patients
101
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$147,905
TrulicityDulaglutide33$63,008
JanuviaSitagliptin Phosphate29$27,432
EliquisApixaban14$20,808
Losartan Potassium460$5,332
Rosuvastatin Calcium236$4,299
Atorvastatin Calcium284$2,988
Levothyroxine Sodium134$2,091
Sildenafil Citrate20$1,939
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,931
Metformin Hcl ErMetformin Hcl113$1,710
PaxlovidNirmatrelvir/Ritonavir16$1,377
Hydrochlorothiazide144$1,206
Escitalopram Oxalate43$1,192
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen62$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$630$147,905126 claims
Lilly USA, LLCTrulicity$686$63,00833 claims
MerckJanuvia$182$27,43229 claims
PfizerEliquis, Paxlovid$456$22,18530 claims
AbbVieSynthroid$1,018$69411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →